Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:FOLDNASDAQ:LGNDNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsFOLDAmicus Therapeutics$6.09-1.6%$7.77$5.93▼$12.65$1.88B0.642.73 million shs5.66 million shsLGNDLigand Pharmaceuticals$105.62+2.2%$107.00$72.95▼$129.90$2.04B0.87119,193 shs146,571 shsMNKDMannKind$4.85+1.5%$4.91$4.17▼$7.63$1.47B1.142.38 million shs1.86 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FOLDAmicus Therapeutics-5.21%-17.69%-17.47%-36.71%-40.14%LGNDLigand Pharmaceuticals-2.85%-7.24%+3.77%-11.93%+41.86%MNKDMannKind-3.63%-2.65%+0.84%-15.25%+8.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFOLDAmicus Therapeutics4.2108 of 5 stars3.42.00.04.33.10.81.9LGNDLigand Pharmaceuticals4.353 of 5 stars3.50.00.04.43.82.51.9MNKDMannKind3.0432 of 5 stars3.62.00.00.03.50.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/AFOLDAmicus Therapeutics 2.70Moderate Buy$16.22166.37% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.4338.64% UpsideMNKDMannKind 3.22Buy$9.5697.16% UpsideCurrent Analyst Ratings BreakdownLatest AVEO, LGND, FOLD, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/27/2025MNKDMannKindWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.002/20/2025FOLDAmicus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$18.00 ➝ $17.002/20/2025FOLDAmicus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/10/2025MNKDMannKindWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$11.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28FOLDAmicus Therapeutics$543.14M3.45N/AN/A$0.63 per share9.67LGNDLigand Pharmaceuticals$167.13M12.18$4.33 per share24.39$40.39 per share2.62MNKDMannKind$285.50M5.16N/AN/A($0.91) per share-5.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AFOLDAmicus Therapeutics-$151.58M-$0.09N/A14.161.51-10.62%12.44%2.60%N/ALGNDLigand Pharmaceuticals$52.15M-$0.1642.0828.47N/A29.68%4.95%4.39%5/8/2025 (Estimated)MNKDMannKind-$11.94M$0.1069.2921.09N/A8.07%-17.74%8.68%5/8/2025 (Estimated)Latest AVEO, LGND, FOLD, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23N/AN/AN/A$37.84 millionN/A5/8/2025Q1 2025MNKDMannKind$0.03N/AN/AN/A$75.86 millionN/A2/26/2025Q4 2024MNKDMannKind$0.03$0.03N/A$0.03$74.99 million$76.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35FOLDAmicus Therapeutics2.013.392.42LGNDLigand PharmaceuticalsN/A12.4911.81MNKDMannKindN/A4.544.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals5.90%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableLGNDLigand Pharmaceuticals8019.28 million17.78 millionOptionableMNKDMannKind400303.85 million267.51 millionOptionableAVEO, LGND, FOLD, and MNKD HeadlinesRecent News About These CompaniesMannKind Q1 2025 Earnings PreviewMay 7 at 5:37 PM | msn.comFreestone Grove Partners LP Makes New Investment in MannKind Co. (NASDAQ:MNKD)May 7 at 4:53 AM | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from AnalystsMay 6 at 2:36 AM | marketbeat.comMannKind (MNKD) to Release Earnings on ThursdayMay 5 at 2:41 AM | marketbeat.comManatuck Hill Partners LLC Acquires 75,000 Shares of MannKind Co. (NASDAQ:MNKD)May 4 at 6:53 AM | marketbeat.comVoya Investment Management LLC Trims Position in MannKind Co. (NASDAQ:MNKD)May 4 at 4:20 AM | marketbeat.comFirst Trust Advisors LP Makes New Investment in MannKind Co. (NASDAQ:MNKD)May 4 at 3:44 AM | marketbeat.comApollo Management Holdings L.P. Sells 300,000 Shares of MannKind Co. (NASDAQ:MNKD)May 2, 2025 | marketbeat.comMannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025May 1, 2025 | globenewswire.comRaymond James Financial Inc. Takes Position in MannKind Co. (NASDAQ:MNKD)April 29, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Sold by Nitorum Capital L.P.April 28, 2025 | marketbeat.comOberweis Asset Management Inc. Has $6.23 Million Stock Holdings in MannKind Co. (NASDAQ:MNKD)April 27, 2025 | marketbeat.comMariner LLC Buys New Stake in MannKind Co. (NASDAQ:MNKD)April 27, 2025 | marketbeat.comInvesco Ltd. Lowers Stock Position in MannKind Co. (NASDAQ:MNKD)April 27, 2025 | marketbeat.comMarshall Wace LLP Buys 214,873 Shares of MannKind Co. (NASDAQ:MNKD)April 26, 2025 | marketbeat.comWalleye Capital LLC Lowers Stock Holdings in MannKind Co. (NASDAQ:MNKD)April 26, 2025 | marketbeat.comEversept Partners LP Has $5.86 Million Position in MannKind Co. (NASDAQ:MNKD)April 24, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 330,100 Shares of MannKind Co. (NASDAQ:MNKD)April 21, 2025 | marketbeat.comWells Fargo & Company MN Sells 209,520 Shares of MannKind Co. (NASDAQ:MNKD)April 21, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 190,563 Shares of MannKind Co. (NASDAQ:MNKD)April 20, 2025 | marketbeat.comMizuho Upgrades MannKind (NASDAQ:MNKD) to Strong-BuyApril 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVEO, LGND, FOLD, and MNKD Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Amicus Therapeutics NASDAQ:FOLD$6.09 -0.10 (-1.62%) Closing price 04:00 PM EasternExtended Trading$6.34 +0.25 (+4.02%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$105.62 +2.30 (+2.23%) Closing price 04:00 PM EasternExtended Trading$105.71 +0.09 (+0.09%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$4.85 +0.07 (+1.46%) Closing price 04:00 PM EasternExtended Trading$4.84 0.00 (-0.10%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
